Gain Therapeutics (GANX) risk factors, FY2025 10-K

Risks Related to Product Development, Regulatory Approval, Manufacturing and Commercialization

1. 01We are subject to extensive and costly government regulation, which are subject to change
2. 02Our long-term success depends heavily on our ability to fund and complete research and development activities and obtain regulatory approval for our product candidates
3. 03Delays in preclinical studies and clinical trials could significantly increase our product development costs and delay product commercialization. In addition, many of the factors that may cause or lead to a delay in the clinical trials may also ultimately lead to denial of regulatory approval of a product candidate
4. 04Some of the disorders we seek to treat have low prevalence and it may be difficult to identify patients with these disorders, which may lead to delays in enrollment for our trials or slower commercial revenue if approved, and we may also face enrollment challenges as a result of other factors
5. 05Our product candidates are novel and still in development. If we are unable to successfully develop, receive regulatory approval for and commercialize our current or future product candidates, our business will be harmed
6. 06Success in early preclinical studies or clinical trials may not be indicative of results obtained in later preclinical studies and clinical trials
7. 07The approach we are taking to discover and develop our product candidates is novel and may never lead to marketable products
8. 08We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
9. 09Clinical trials required for our product candidates are expensive and time-consuming, and their outcome is uncertain
10. 10We have limited experience as a company conducting clinical trials and may be unable to complete pivotal clinical trials for any product candidates we may develop
11. 11If we decide to pursue a Fast Track Designation or comparable foreign regulatory procedures for some of our product candidates, it may not lead to a faster development or regulatory review or approval process
12. 12If we decide to seek Orphan Drug Designation for some of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for supplemental market exclusivity
13. 13We do not have, and may never obtain, the regulatory approvals we need to market our product candidates
14. 14Our product candidates may cause serious adverse events (“SAEs”) or undesirable side effects which may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales
15. 15Even if approved, our products will be subject to extensive post-approval regulation
16. 16Even if we obtain regulatory approval to market our product candidates, our product candidates may not be accepted by the market

Risks Related to Our Financial Condition and Capital Requirements; Competition

1. 17In addition, government funding of the SEC and other government agencies on which our operations may rely, and those that fund research and development activities that is required by third parties we enter into agreements with, is subject to the political process, which is inherently fluid and unpredictableNew
2. 18We face intense competition in the markets targeted by our product candidates. Many of our competitors have substantially greater resources than we do and we expect that all our product candidates under development will face intense competition from existing or future drugs
3. 19Competition and technological change may make our product candidates and technologies less attractive or obsolete
4. 20Our business and operations may be adversely affected by health epidemics or pandemics

Risks Related to Our Intellectual Property

1. 21Our success depends substantially upon our ability to obtain and maintain intellectual property protection relating to our products and technologies
2. 22If we fail to protect our intellectual property rights, our ability to pursue the development of our technologies and products would be negatively affected39% rewritten
3. 23narrower than anticipated which could deprive us of rights necessary for the successful commercialization of our product candidatesNew
4. 24We may be involved in lawsuits to protect or enforce our patents, which could be expensive and time consuming
5. 25If we infringe the rights of third parties, we could be prevented from selling products or forced to pay damages and defend against litigation

Risks Related to Third Parties and Collaborators

1. 26We currently rely on, and intend to rely on in the future, third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business
2. 27Third-party manufacturers must be inspected by the FDA and comparable foreign regulatory authorities for cGMP compliance before they can produce commercial products
3. 28Corporate and academic collaborators may take actions to delay, prevent, or undermine the success of our products
4. 29Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results55% rewritten
5. 30International trade policies, including tariffs, sanctions and trade barriers may adversely affect our current and future business, financial condition, results of operations and prospectsNew
6. 31tariffs and trade restrictions could hinder our ability to establish cost-effective production capabilities and international operations, negatively impacting our growth prospectsNew
7. 32Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading, or incomplete
8. 33Global and macroeconomic conditions, including economic, political and social instability, could adversely affect our financial condition or results of operations
9. 34We will need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth
10. 35We depend upon our key personnel and our ability to attract and retain qualified employees
11. 36Under applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees
12. 37Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws69% rewritten
13. 38Medicaid or comparable foreign programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operationsNew
14. 39Coverage and adequate reimbursement may not be available for our current or any future product candidates, which could make it difficult for us to sell profitably, if approved
15. 40Healthcare legislative reform measures may have a negative impact on our business and results of operations90% rewritten
16. 41If we obtain approval to commercialize any approved products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business
17. 42Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may develop
18. 43Issues relating to the use of AI and machine learning could adversely affect our business and operating results
19. 44We have been, and in the future may be, involved in legal proceedings that may have a negative impact on our businessNew

Risks Related to Ownership of Our Common Stock

1. 45The market price for our common stock has been and likely will continue to be volatile, and your investment in our securities could decline in value43% rewritten
2. 46such conflict between Russia, the United States and countries in Europe as well as other countries such as China; andNew
3. 47We incur and will continue to incur costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices
4. 48We are an “emerging growth company,” and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors
5. 49all, and may result in the potential loss of confidence by investors, suppliers, and employees and lead to fewer business development opportunities. Additionally, the market price of our common stock may decline further, and stockholders may lose some or all of their investmentNew
6. 50Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
7. 51Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition, or results of operations63% rewritten
8. 52We do not anticipate paying dividends on our common stock and, accordingly, stockholders must rely on stock appreciation for any return on their investment
9. 53Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall
10. 54The rights of the holders of our securities may be impaired by the potential issuance of preferred stock
11. 55If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline
12. 56Anti-takeover provisions in our organizational documents and Delaware law might discourage or delay attempts to acquire us that you might consider favorable
13. 57Provisions in our organizational documents regarding exculpation and indemnification of our directors and officers may result in substantial expenditures by us and may discourage lawsuits against our directors and officers